EA201791074A1 - Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина - Google Patents
Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуинаInfo
- Publication number
- EA201791074A1 EA201791074A1 EA201791074A EA201791074A EA201791074A1 EA 201791074 A1 EA201791074 A1 EA 201791074A1 EA 201791074 A EA201791074 A EA 201791074A EA 201791074 A EA201791074 A EA 201791074A EA 201791074 A1 EA201791074 A1 EA 201791074A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- disorders
- ureal
- analogues
- substituted
- Prior art date
Links
- 102000011990 Sirtuin Human genes 0.000 title abstract 2
- 108050002485 Sirtuin Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010020565 Hyperaemia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение относится к новым замещенным соединениям - аналогам мочевины с мостиковой связью формулы (I) или их фармацевтически приемлемым солям, соответствующим фармацевтическим композициям, способам получения и применению таких соединений, отдельно или в комбинации с другими терапевтическими агентами, такими как модуляторы сиртуина, используемыми для увеличения продолжительности жизни клетки, и при лечении и/или предупреждении широкого спектра заболеваний и нарушений, которые включают, но этим не ограничиваются, например, заболевания или расстройства, связанные со старением или стрессом, диабетом, ожирением, нейродегенеративными заболеваниями, сердечно-сосудистым заболеванием, нарушениями свертывания крови, воспалением, злокачественным новообразованием и/или гиперемией, а также заболеваниями или расстройствами, лечению которых будет способствовать увеличение активности митохондрий.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081916P | 2014-11-19 | 2014-11-19 | |
| PCT/IB2015/058978 WO2016079710A1 (en) | 2014-11-19 | 2015-11-19 | Substituted bridged urea analogs as sirtuin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201791074A1 true EA201791074A1 (ru) | 2017-10-31 |
Family
ID=54705247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791074A EA201791074A1 (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20180319810A1 (ru) |
| EP (4) | EP3220918A1 (ru) |
| JP (4) | JP2017534663A (ru) |
| KR (4) | KR20170087907A (ru) |
| CN (4) | CN107108627A (ru) |
| AU (4) | AU2015348943A1 (ru) |
| BR (4) | BR112017010601A2 (ru) |
| CA (4) | CA2968029A1 (ru) |
| CL (1) | CL2017001275A1 (ru) |
| CO (1) | CO2017004994A2 (ru) |
| CR (1) | CR20170209A (ru) |
| DO (1) | DOP2017000123A (ru) |
| EA (1) | EA201791074A1 (ru) |
| ES (1) | ES2823748T3 (ru) |
| IL (1) | IL252252A0 (ru) |
| MX (1) | MX2017006658A (ru) |
| PE (1) | PE20171257A1 (ru) |
| PH (1) | PH12017500913A1 (ru) |
| RU (3) | RU2017120857A (ru) |
| SG (1) | SG11201703824QA (ru) |
| WO (4) | WO2016079712A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10653782B2 (en) * | 2014-11-25 | 2020-05-19 | Nortwestern University | Retroviral particles expressing Sirt1 embedded within PPCN |
| CN108329388A (zh) * | 2018-01-18 | 2018-07-27 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的沉默配型信息调节蛋白突变蛋白及其应用 |
| CN108707150B (zh) * | 2018-05-14 | 2021-04-16 | 江苏惠利生物科技有限公司 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN108395436B (zh) * | 2018-05-14 | 2021-01-12 | 鹤壁市人民医院 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN110478339A (zh) * | 2019-08-12 | 2019-11-22 | 昆明理工大学 | 紫铆因在制备靶向恢复突变p53构象药物中的应用 |
| WO2021043703A1 (de) * | 2019-09-02 | 2021-03-11 | Merck Patent Gmbh | Materialien für organische elektrolumineszenzvorrichtungen |
| CN114890955A (zh) * | 2022-06-23 | 2022-08-12 | 江西瑞威尔生物科技有限公司 | 一种n取代吗啉类有机化合物的制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
| UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
| ES2574927T3 (es) * | 2009-10-29 | 2016-06-23 | Glaxosmithkline Llc | Piridinas bicíclicas y análogos como moduladores de sirtuina |
| CA2857512A1 (en) * | 2011-12-12 | 2013-06-20 | Smb Innovation Aps | Novel heterocyclic compounds useful in sirtuin binding and modulation |
| EP2997029B1 (en) * | 2013-05-13 | 2019-01-09 | GlaxoSmithKline LLC | Substituted bridged urea analogs as sirtuin modulators |
-
2015
- 2015-11-19 CA CA2968029A patent/CA2968029A1/en not_active Abandoned
- 2015-11-19 BR BR112017010601A patent/BR112017010601A2/pt not_active Application Discontinuation
- 2015-11-19 WO PCT/IB2015/058981 patent/WO2016079712A1/en active Application Filing
- 2015-11-19 JP JP2017526875A patent/JP2017534663A/ja not_active Withdrawn
- 2015-11-19 CN CN201580073311.3A patent/CN107108627A/zh active Pending
- 2015-11-19 EP EP15804601.1A patent/EP3220918A1/en not_active Withdrawn
- 2015-11-19 EP EP15801271.6A patent/EP3221317B1/en active Active
- 2015-11-19 CN CN201580073897.3A patent/CN107207509B/zh not_active Expired - Fee Related
- 2015-11-19 KR KR1020177016279A patent/KR20170087907A/ko not_active Withdrawn
- 2015-11-19 US US15/527,941 patent/US20180319810A1/en not_active Abandoned
- 2015-11-19 EA EA201791074A patent/EA201791074A1/ru unknown
- 2015-11-19 RU RU2017120857A patent/RU2017120857A/ru unknown
- 2015-11-19 WO PCT/IB2015/058977 patent/WO2016079709A1/en active Application Filing
- 2015-11-19 KR KR1020177016280A patent/KR20170083135A/ko not_active Withdrawn
- 2015-11-19 AU AU2015348943A patent/AU2015348943A1/en not_active Abandoned
- 2015-11-19 CA CA2968030A patent/CA2968030A1/en not_active Abandoned
- 2015-11-19 CA CA2968027A patent/CA2968027A1/en not_active Abandoned
- 2015-11-19 EP EP15816522.5A patent/EP3221322A1/en not_active Withdrawn
- 2015-11-19 CR CR20170209A patent/CR20170209A/es unknown
- 2015-11-19 ES ES15801271T patent/ES2823748T3/es active Active
- 2015-11-19 AU AU2015348944A patent/AU2015348944A1/en not_active Abandoned
- 2015-11-19 US US15/527,440 patent/US20170355705A1/en not_active Abandoned
- 2015-11-19 US US15/527,581 patent/US10072011B2/en not_active Expired - Fee Related
- 2015-11-19 MX MX2017006658A patent/MX2017006658A/es unknown
- 2015-11-19 US US15/527,851 patent/US20190048016A1/en not_active Abandoned
- 2015-11-19 WO PCT/IB2015/058980 patent/WO2016079711A1/en active Application Filing
- 2015-11-19 PE PE2017000883A patent/PE20171257A1/es not_active Application Discontinuation
- 2015-11-19 AU AU2015348942A patent/AU2015348942B2/en not_active Ceased
- 2015-11-19 KR KR1020177016278A patent/KR20170083134A/ko not_active Withdrawn
- 2015-11-19 BR BR112017010595-0A patent/BR112017010595A2/pt not_active Application Discontinuation
- 2015-11-19 JP JP2017526950A patent/JP2017534664A/ja active Pending
- 2015-11-19 BR BR112017010602A patent/BR112017010602A2/pt not_active Application Discontinuation
- 2015-11-19 SG SG11201703824QA patent/SG11201703824QA/en unknown
- 2015-11-19 AU AU2015348941A patent/AU2015348941A1/en not_active Abandoned
- 2015-11-19 EP EP15801270.8A patent/EP3221316A1/en not_active Withdrawn
- 2015-11-19 JP JP2017526852A patent/JP6806679B2/ja not_active Expired - Fee Related
- 2015-11-19 CA CA2968032A patent/CA2968032A1/en not_active Abandoned
- 2015-11-19 CN CN201580073769.9A patent/CN107207520A/zh active Pending
- 2015-11-19 BR BR112017010599A patent/BR112017010599A2/pt not_active Application Discontinuation
- 2015-11-19 KR KR1020177016277A patent/KR20170083133A/ko not_active Withdrawn
- 2015-11-19 RU RU2017120858A patent/RU2017120858A/ru unknown
- 2015-11-19 WO PCT/IB2015/058978 patent/WO2016079710A1/en active Application Filing
- 2015-11-19 JP JP2017526965A patent/JP2017534665A/ja active Pending
- 2015-11-19 RU RU2017120855A patent/RU2017120855A/ru unknown
- 2015-11-19 CN CN201580073782.4A patent/CN107207521A/zh active Pending
-
2017
- 2017-05-11 IL IL252252A patent/IL252252A0/en unknown
- 2017-05-17 PH PH12017500913A patent/PH12017500913A1/en unknown
- 2017-05-18 DO DO2017000123A patent/DOP2017000123A/es unknown
- 2017-05-18 CL CL2017001275A patent/CL2017001275A1/es unknown
- 2017-05-19 CO CONC2017/0004994A patent/CO2017004994A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791074A1 (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
| EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| EA201690246A1 (ru) | Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл | |
| EA201391561A1 (ru) | Новые соединения-модуляторы gpr-119 | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201790781A2 (ru) | Противовирусные соединения | |
| EA201591087A1 (ru) | Новые производные бензимидазола в качестве антагонистов рецептора ep4 | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| BR112017010592A2 (pt) | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína | |
| EA201591244A1 (ru) | Противовирусные соединения | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| EA202091396A1 (ru) | Композиции и способы лечения метаболических состояний | |
| EA201690520A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
| EA201691293A1 (ru) | Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h | |
| EA201890767A1 (ru) | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений | |
| EA201890245A1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA202091433A1 (ru) | Новые производные бензамида в качестве модуляторов ppar-гамма | |
| EA201690972A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) |